Neurocrine Biosciences Acquires Soleno Therapeutics for $2.9 Billion
Event summary
- Neurocrine Biosciences completed its $2.9 billion acquisition of Soleno Therapeutics on May 18, 2026.
- The deal adds VYKAT™ XR, the first FDA-approved treatment for hyperphagia in Prader-Willi syndrome, to Neurocrine's portfolio.
- Neurocrine paid $53.00 per share for Soleno, with 88.9% of shares tendered by the expiration deadline.
- Soleno's stock will no longer be listed on the Nasdaq Capital Market as of May 18, 2026.
The big picture
Neurocrine's acquisition of Soleno strengthens its position in the rare disease and endocrinology sectors, adding a commercially available treatment to its portfolio. The deal reflects a broader trend of biopharmaceutical companies consolidating to enhance their portfolios and address unmet medical needs. With a total equity value of $2.9 billion, the acquisition underscores Neurocrine's commitment to expanding its reach in the treatment of complex neurological and metabolic disorders.
What we're watching
- Commercial Execution
- How Neurocrine will integrate and scale VYKAT XR's commercial potential in the Prader-Willi syndrome market.
- Pipeline Expansion
- Whether the acquisition will accelerate Neurocrine's pipeline in rare disease and endocrinology.
- Market Uptake
- The pace at which VYKAT XR gains market adoption among the 10,000 U.S. patients with Prader-Willi syndrome.
Related topics